(Q38312367)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

review article

1 reference

title

FDG PET/CT imaging as a biomarker in lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Michel Meignan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Andrea Gallamini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Anas Younes

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

9 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

623-633

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-014-2973-6

27 February 2020

exact match

0 references

cites work

International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Treatment of Hodgkin lymphoma: a 50-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Tumor glycolysis as a target for cancer therapy: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

XIV. The rationale for combining targeted and biological anti-lymphoma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Optimising the lymphoma response criteria in the era of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2973-6

Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells

21 January 2018

1 reference

12 December 2020

Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma

1 reference

12 December 2020

Guidelines for the first line management of classical Hodgkin lymphoma

1 reference

12 December 2020

Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study

1 reference

12 December 2020

10.1007/S00259-014-2973-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25573631%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference